Status:
COMPLETED
Can Measurement of Neutrophil-derived ROS Production be a Novel Biomarker of Sepsis?
Lead Sponsor:
Gazi University
Collaborating Sponsors:
Seroxo Ltd
Conditions:
Infections
Sepsis
Eligibility:
All Genders
18+ years
Brief Summary
Neutrophils are indispensable for host defense and have an important roles in modulating the immune system in both the innate and adaptive immune response. Neutrophils operate using a number of differ...
Detailed Description
Introduction: Sepsis is defined as the dysregulated host response to infection leading to organ dysfunction. Both sepsis and septic shock are important health problems affecting millions of people, r...
Eligibility Criteria
Inclusion
- Diagnosis or suspicion of various infectious disease with or without sepsis and admitted to the ICU or inpatient service due to this clinical diagnosis for patient group
- Patients followed in the inpatient service due to various non-infectious diseases and outpatients who were examined in outpatient clinics for control group
Exclusion
- patient or control group under the age of 18 years
- Patients died within the 24 hours after hospital admission
- Patients who did not sign informed consent
- Refusal of legal representative to participate in the study in unconscious patients
- Patients with an absolute neutrophil count \<500/mm3 on admission
- Control group describing any infective symptoms
- Control group with a chronic infectious disease under treatment
Key Trial Info
Start Date :
June 28 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2023
Estimated Enrollment :
276 Patients enrolled
Trial Details
Trial ID
NCT05968287
Start Date
June 28 2022
End Date
January 31 2023
Last Update
August 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gazi University
Ankara, Yenimahalle, Turkey (Türkiye), 06560